Press release content from Business Wire. The AP news staff was not involved in its creation.
Nexign and MegaFon Introduced the Unified Billing to Facilitate Digital Transformation
March 17, 2021 GMT
SAINT PETERSBURG, Russia (BUSINESS WIRE) Mar 17, 2021
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, and MegaFon, the pan-Russian operator of digital opportunities, have completed the project of unifying billing systems for all 8 MegaFon’s subsidiaries on a single BSS platform. The companies also migrated subscriber data to the new environment with no impact on customers.
ADVERTISEMENT
The need to go beyond classical telecom services pushed MegaFon to transform the billing core and develop a unified billing system in order to facilitate digital transformation. Among the strategic goals of the project were the reduction of total cost of ownership (TCO) by 20–30% and acceleration of new product launche
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce .
Amarin Corporation plcMarch 17, 2021 GMT
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
Intec Pharma LtdMarch 17, 2021 GMT
JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on Intec’s website, www.intecpharma.com, by selecting “Investors” and then “Financials” and “SEC Filings”.
You may request a copy of the Company’s Form 10-K, at no cost to you, by writing to the Chief Financial Officer of the Company at 12 Hartom Street, Har Hotzvim, Jerusalem 9777512, Israel or by calling the Company at +972 (2) 586 4657.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Intelligent Systems to Participate in Sidoti 2021 Virtual Investor Conference
Intelligent Systems CorporationMarch 17, 2021 GMT
NORCROSS, Ga., March 17, 2021 (GLOBE NEWSWIRE) Intelligent Systems Corporation [NYSE American: INS], the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today that Chief Executive Officer, Leland Strange, and Chief Financial Officer, Matt White, will present at the Sidoti Virtual Investor Conference on March 24, 2021 at 10:45 a.m. ET.
ADVERTISEMENT
About Intelligent Systems Corporation For over thirty-five years, Intelligent Systems Corporation [NYSE American: INS] has identified, created, operated and grown technology companies. The company’s principal operations are CoreCard Software, Inc. ( www.corecard.com ) and its affiliate companies. CoreCard provides p
Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results
March 17, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) Mar 17, 2021
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year ended December 31, 2020.
“Notwithstanding the challenges everyone faced in 2020, IMV’s commitment to provide effective and well-tolerated immunotherapies to patients with hard-to-treat cancer resulted in significant progress on multiple fronts with our lead compound, Maveropepimut-S, and with other DPX-based candidates,” said Fred Ors, Chief Executive Officer at IMV Inc. “We see 2021 as a transformational year for IMV as we are advancing Maveropepimut-S in both relapsed, refractory DLBC